A Randomised, Double-blind, Placebo-controlled, Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Anti-C5a monoclonal antibody (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Sep 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 07 Sep 2012 Planned number of patients changed from 26 to 48 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History